Trevi Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.12.24	Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? (Benzinga)
12.12.24	Trevi Reports Positive Outcome From Sample Size Re-estimation For Phase 2b CORAL Study; Stock Up (RTTNews)
20.03.24	Trevi Therapeutics: Q4 Earnings Insights (Benzinga)
19.03.24	Earnings Outlook For Trevi Therapeutics (Benzinga)
05.12.23	Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) (PR Newswire)
09.11.23	Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
02.11.23	Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough (PR Newswire)
01.11.23	Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023 (PR Newswire)
13.10.23	Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis (PR Newswire)
06.09.23	Trevi Therapeutics to Participate in Upcoming September Events (PR Newswire)
10.08.23	Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
03.08.23	Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023 (PR Newswire)
01.08.23	Trevi Therapeutics to Participate in Upcoming August Events (PR Newswire)
06.07.23	Trevi Therapeutics to Participate in Upcoming July Investor Events (PR Newswire)
30.05.23	Trevi Therapeutics to Participate in Upcoming June Conferences (PR Newswire)
22.05.23	Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence (PR Newswire)
11.05.23	Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
09.05.23	Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023 (PR Newswire)
04.05.23	Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 (PR Newswire)
02.05.23	Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference (PR Newswire)
27.04.23	Trevi Therapeutics to Participate in Upcoming May Investor Events (PR Newswire)
11.04.23	Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference (PR Newswire)
16.03.23	Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update (PR Newswire)
09.03.23	Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023 (PR Newswire)
08.03.23	Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis (PR Newswire)
06.03.23	Trevi Therapeutics to Participate in Upcoming March Conferences (PR Newswire)
16.02.23	Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 (PR Newswire)
02.02.23	Trevi Therapeutics to Present and Participate in Upcoming February Conferences (PR Newswire)
05.01.23	Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences (PR Newswire)
28.12.22	Biotech Penny Stocks That Delivered Impressive Gains In 2022 (RTTNews)
19.12.22	Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference (PR Newswire)
14.11.22	Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer (PR Newswire)
10.11.22	Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
08.11.22	Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference (PR Newswire)
03.11.22	Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022 (PR Newswire)
27.10.22	Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting (PR Newswire)
23.09.22	Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering (PR Newswire)
22.09.22	Trevi Therapeutics Announces Proposed Public Offering (PR Newswire)
19.09.22	Trevi Reports Positive Results From Full Set Of Subjects From CANAL Trial Of Haduvio (RTTNews)
19.09.22	Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis (PR Newswire)
07.09.22	Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
30.08.22	Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022 (PR Newswire)
24.08.22	Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release (PR Newswire)
11.08.22	Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update (PR Newswire)
09.08.22	Trevi Therapeutics to Present at Upcoming August Conferences (PR Newswire)
04.08.22	Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022 (PR Newswire)
07.07.22	Trevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS) (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swiss Re	133.55	4.50 %	K V
Swiss Life Hldg	693.60	0.93 %	K V
Zurich Insur Gr	552.80	0.91 %	K V
Kuehne+Nagel Int	206.60	0.78 %	K V
Sonova Hldg	294.00	0.58 %	K V
Sika	228.20	-1.04 %	K V
Part Grp Hldg	1’264.50	-1.56 %	K V
Geberit	538.20	-1.61 %	K V
Alcon	75.22	-1.75 %	K V
Lonza Grp	532.80	-2.81 %	K V

Nachrichten zu Trevi Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten